Literature DB >> 24768728

Formulating SLMs as oral pulsatile system for potential delivery of melatonin to pediatric population.

Beatrice Albertini1, Marcello Di Sabatino2, Cecilia Melegari2, Nadia Passerini2.   

Abstract

The formulation development of melatonin (MLT) for infants and children with neurodevelopmental difficulties was fully investigated. This population have a higher prevalence of sleep disorders and present special challenges for drug administration and swallowing. To solve these issues, solid lipid microparticles (SLMs) were designed to obtain an oral flexible dosage form constituted by GRAS excipients and a free flow pulsatile delivery system for MLT, able to maintain its release through 8h. Three groups of SLMs were produced by spray congealing and characterized as regards particle size, morphology, flowability, solid state, drug content and release behavior. The SLMs manipulation with milk and yogurt and the MLT stability in these foods were also investigated. Microparticles with different excipient composition were selected to obtain a pulsatile release pattern over 8h. The final delivery platform displayed a prompt release from group I SLMs together with a lag phase of groups II and III SLMs, followed by a repeated MLT release from group II and a prolonged MLT release related to the last group. Finally, MLT was compatible and stable in milk and yogurt suggesting that microparticles sprinkled into food is acceptable for MLT administration to children unable to swallow capsules or tablets.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dose flexibility; Melatonin; Oral pediatric formulation; Solid-lipid microparticles; Spray congealing; Stability in food

Mesh:

Substances:

Year:  2014        PMID: 24768728     DOI: 10.1016/j.ijpharm.2014.04.055

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

1.  Zero-order release of poorly water-soluble drug from polymeric films made via aqueous slurry casting.

Authors:  Lu Zhang; Joy Alfano; Doran Race; Rajesh N Davé
Journal:  Eur J Pharm Sci       Date:  2018-02-27       Impact factor: 4.384

Review 2.  Toxicology of Blister Agents: Is Melatonin a Potential Therapeutic Option?

Authors:  Alejandro Romero; Eva Ramos; Francisco López-Muñoz; Cristóbal De Los Ríos; Javier Egea; Emilio Gil-Martín; René Pita; Juan J Torrado; Dolores R Serrano; Antonio Juberias
Journal:  Diseases       Date:  2021-04-10

Review 3.  Formulation approaches to pediatric oral drug delivery: benefits and limitations of current platforms.

Authors:  Felipe L Lopez; Terry B Ernest; Catherine Tuleu; Mine Orlu Gul
Journal:  Expert Opin Drug Deliv       Date:  2015-07-13       Impact factor: 6.648

4.  Application of a validated HPLC-PDA method for the determination of melatonin content and its release from poly(lactic acid) nanoparticles.

Authors:  Leiziani Gnatkowski Martins; Najeh Maissar Khalil; Rubiana Mara Mainardes
Journal:  J Pharm Anal       Date:  2017-05-20

Review 5.  Melatonin-Loaded Nanocarriers: New Horizons for Therapeutic Applications.

Authors:  Luiz Gustavo de Almeida Chuffa; Fábio Rodrigues Ferreira Seiva; Adriana Alonso Novais; Vinícius Augusto Simão; Virna Margarita Martín Giménez; Walter Manucha; Debora Aparecida Pires de Campos Zuccari; Russel J Reiter
Journal:  Molecules       Date:  2021-06-10       Impact factor: 4.411

6.  Carbamazepine Gel Formulation as a Sustained Release Epilepsy Medication for Pediatric Use.

Authors:  Saeid Mezail Mawazi; Sinan Mohammed Abdullah Al-Mahmood; Bappaditya Chatterjee; Hazrina Ab Hadi; Abd Almonem Doolaanea
Journal:  Pharmaceutics       Date:  2019-09-20       Impact factor: 6.321

7.  Formulation of Lipid-Based Tableted Spray-Congealed Microparticles for Sustained Release of Vildagliptin: In Vitro and In Vivo Studies.

Authors:  Khaled H Al Zahabi; Hind Ben Tkhayat; Ehab Abu-Basha; Al Sayed Sallam; Husam M Younes
Journal:  Pharmaceutics       Date:  2021-12-15       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.